KPNB1: Key Regulator of Intracellular Signaling Pathways and Neurodegenerative Diseases

Target Name: KPNB1

NCBI ID: G3837

KPNB1

KPNB1: Key Regulator of Intracellular Signaling Pathways and Neurodegenerative Diseases

KPNB1 (Importin subunit beta-1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and blood vessels. It is a key regulator of intracellular signaling pathways, including the regulation of cell adhesion, migration, and survival. KPNB1 has also been shown to play a role in the regulation of pain perception and neurodegenerative diseases.

Diseases associated with KPNB1

KPNB1 has been implicated in a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroglial cells.

Alzheimer's disease is a degenerative brain disorder that is characterized by the progressive accumulation of neurofibrillary tangles and the loss of brain cells. The most common cause of Alzheimer's disease is the presence of beta-amyloid plaques, which are thought to disrupt the normal functioning of KPNB1.

Parkinson's disease is a neurodegenerative disorder that is characterized by the progressive loss of dopamine-producing neurons in the brain. The underlying cause of Parkinson's disease is thought to be the dysfunction of KPNB1, which has been shown to play a role in the regulation of dopamine release.

Huntington's disease is a neurodegenerative disorder that is characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. The most common cause of Huntington's disease is the presence of huntingtin, which is a protein that is expressed in the brain and is thought to be regulated by KPNB1.

The potential therapeutic targets for KPNB1 include drugs that can modulate the activity of KPNB1, as well as biomarkers that can be used to diagnose and monitor the progression of neurodegenerative diseases.

The role of KPNB1 in cell adhesion and migration

KPNB1 plays a key role in the regulation of cell adhesion and migration. It is a critical regulator of the process of cell-cell adhesion, which is the interaction between cells that results in the formation of tight junctions and adherens junctions. These structures are important for maintaining tissue structure and function, and are involved in the regulation of various physiological processes, including embryonic development, tissue repair, and cancer progression.

KPNB1 is also involved in the regulation of cell migration, which is the movement of cells through the body's various tissues. This process is critical for the development and maintenance of tissues and organs, and is involved in the regulation of various physiological processes, including embryonic development, tissue repair, and cancer progression.

The dysfunction of KPNB1 has been implicated in the development of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroglial cells. The most common cause of Alzheimer's disease is the presence of beta-amyloid plaques, which are thought to disrupt the normal functioning of KPNB1.

The potential therapeutic targets for KPNB1 include drugs that can modulate the activity of KPNB1, as well as biomarkers that can be used to diagnose and monitor the progression of neurodegenerative diseases.

Conclusion

KPNB1 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and blood vessels. It is a key regulator of intracellular signaling pathways, including the regulation of cell adhesion, migration, and survival. KPNB1 has also been shown to play a role in the regulation of pain perception and neurodegenerative diseases. The dysfunction of KPNB1 has been implicated in the development of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The potential therapeutic targets for KPNB1 include drugs that can modulate the activity of KPNB1, as well as biomarkers that can be used to diagnose and monitor the progression of neurodegenerative diseases.

Protein Name: Karyopherin Subunit Beta 1

Functions: Functions in nuclear protein import, either in association with an adapter protein, like an importin-alpha subunit, which binds to nuclear localization signals (NLS) in cargo substrates, or by acting as autonomous nuclear transport receptor. Acting autonomously, serves itself as NLS receptor. Docking of the importin/substrate complex to the nuclear pore complex (NPC) is mediated by KPNB1 through binding to nucleoporin FxFG repeats and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to importin-beta and the three components separate and importin-alpha and -beta are re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran from importin. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Mediates autonomously the nuclear import of ribosomal proteins RPL23A, RPS7 and RPL5 (PubMed:11682607). In association with IPO7, mediates the nuclear import of H1 histone. In vitro, mediates nuclear import of H2A, H2B, H3 and H4 histones. In case of HIV-1 infection, binds and mediates the nuclear import of HIV-1 Rev. Imports SNAI1 and PRKCI into the nucleus

The "KPNB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KPNB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets